In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, liraglutide, and exenatide, have emerged as highly effective agents for inducing substantial weight loss [3]
Can vitamin D deficiency reduce the effectiveness of GLP-1 therapy
brand-name Ozempic undergoes FDA manufacturing oversight, but supply shortages have driven patients toward compounded alternatives with different regulatory pathways
Available from: 4 Morgan Stanley, 2023
Full EVOKE/EVOKE+ results are likely to be discussed further at upcoming scientific meetings (e.g., AD/PD 2026), and ongoing analyses may explore preventive settings (earlier intervention), dose/exposure considerations (e.g., injectable vs
Another analysis based on 6 publications involving 7221 patients could not confirm that GLP-1RA has an ameliorating effect on AD either [54]